News

Article

Pharmaceutical Technology

Pharmaceutical Technology, Regulatory Sourcebook, September 2021
Volume2021 eBook
Issue 3
Pages: 23–33

Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices

Author(s):

Chris Burgess

Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.

Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices.Image: ipopba - Stock.adobe.com

ipopba - Stock.adobe.com

In pharma applications, consistent sampling and testing nomenclature is critical for data integrity and compliance with specifications and regulatory standards. Inconsistent sampling and testing processes can lead to errors, resulting in data integrity issues and potentially incorrect decisions about pharmaceutical quality.

Guidance documents within the pharma industry and other regulated sectors, however, offer conflicting information. This review of regulatory and compendial standards reveals the scope of the problem.

This article provides a review of available analytical nomenclature, recommended naming for individual steps, and terms used in the process flows. Part two of this paper proposes a simplified approach for sampling and testing nomenclature.

Read this article in Pharmaceutical Technology’s September 2021 Regulatory Sourcebook eBook.

About the author

Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook
September 2021
Pages: 23–33

Citation

When referring to this article, please cite it as C. Burgess, “Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).

Articles in this issue
prefilled syringes are combination drug-device products
Understanding Combination Product Regulations
titanium dioxide
Considering Titanium Dioxide Regulatory Changes
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Changing the Course of Drug Shortages
Changing the Course of Drug Shortages
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach Image: ipopba - Stock.adobe.com
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Simplified Approach
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices. Image: ipopba - Stock.adobe.com
Sampling and Testing Nomenclature for Pharmaceutical Analysis: A Review of Current Practices
Industry Organizations Assist Pharma During the Pandemic and Beyond
Industry Organizations Assist Pharma During the Pandemic and Beyond
EU's Pharma Strategy
Mapping Out Pharma’s Regulatory Future in Europe

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 1st 2025

FDA Changes Opioid Pain Medication Labeling Requirements

Susan Haigney
The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 1st 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services. | Image Credit: © Tada Images - stock.adobe.com
August 1st 2025

3 Reasons FDA Says Quality Investments Are Essential for Drug Manufacturers and Patients

Patrick Lavery
FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and help prevent drug shortages.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 1st 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Landkarte *** Europa | Image credit: ©beugdesign - Stock.adobe.com
August 1st 2025

EMA Encourages Use of New Approach Methodologies to Reduce Animal Testing

Cheryl Barton
EMA is phasing out animal testing and is asking pharmaceutical companies to use new approach methodologies.
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
August 1st 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.